Displaying drugs 1576 - 1600 of 2668 in total
APL-502
APL 502 is a humanised immunoglobulin G1 (IgG1) monoclonal antibody targeting the programmed cell death-1 ligand-1 (PD-L1).
Investigational
TG4010
A bivalent cancer vaccine comprised of a modified vaccinia virus Ankara (MVA) strain encoding human mucin 1 (MUC1) and interleukin-2 (IL-2) with potential immunostimulating and antineoplastic activities. Originally developed for the eradication of smallpox, MVA is a highly attenuated and replication-defective strain incapable of virion assembly and exerts potent immunostimulatory...
Investigational
OAV401
Investigational
ARRY-502
ARRY-502 is under investigation in clinical trial NCT01561690 (A Study of ARRY-502 in Patients With Persistent Asthma).
Investigational
RP-A501
RP-A501 is a gene therapy product consisting of a recombinant adeno-associated virus serotype 9 (rAAV9) capsid containing the human LAMP2B transgene (AAV9:LAMP2B), which encodes lysosome-associated membrane protein 2 (LAMP-2). It is being investigated for Danon disease.
Investigational
Tyrphostin AG 835
Experimental
HMR4011
HMR4011 (IPL 576,092) is a novel steroidal anti-inflammatory compound with a mechanism of action distinct from that of glucocorticoid. IPL 576,092 has previously been investigated as a treatment for asthma.
Investigational
Cavrotolimod
Investigational
Saruparib
Saruparib is under investigation in clinical trial NCT06380751 (Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in Hr-positive, Her2-negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or Palb2m Advanced Breast Cancer).
Investigational
Matched Description: … With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in Hr-positive, Her2-negative (IHC 0, …
TP-508
TP508 is a non-proteolytic synthetic peptide representing the portion of human thrombin originally identified as the fibroblast high-affinity receptor binding domain.
Investigational
Bersanlimab
Bersanlimab is an investigational monoclonal antibody directed against intercellular adhesion molecule 1 (ICAM-1).
Investigational
IMT504
IMT504, a non-CpG 24-mer oligodeoxynucleotide, is an immunomodulatory oligonucleotide currently being investigated as a rabies vaccine.
Investigational
Ciliary neurotrophic factor
NT-501 is an intraocular implant that contains human cells that have been genetically modified to secrete ciliary neurotrophic factor (CNTF). It is under investigation for the treatment of retinitis pigmentosa and age-related macular degeneration.
Investigational
HZT-501
HZT-501 is under investigation by Horizon Therapeutics, Inc., a privately held biopharmaceutical company. It has entered Phase 3 clinical trials in March 2007 for reduction of the risk of development of ibuprofen-associated upper gastrointestinal (i.e., gastric and/or duodenal) ulcers. HZT-501 is a combination product including ibuprofen and the acid reducing...
Investigational
CAN-508
Experimental
CBP-501
Investigational
GTP-506
GTP-506 is a gene therapy formed by two vectors, a nuclease vector targeting gene editing in the well-characterized PCSK9 gene locus and a therapeutic donor vector that inserts the OTC gene to provide the desired genetic correction.
Investigational
ANC-501
ANC-501 is under investigation in clinical trial NCT05439603 (ANC-501 in the Treatment of Adults With Major Depressive Disorder).
Investigational
ATYR-1940
Investigational
NDI-5001
Investigational
MOD-5014
MOD-5014 is a long-acting carboxy-terminal peptide (CTP)-modified Factor IIa. It is being investigated for the treatment of hemophilia.
Investigational
BHV-5000
BHV-5000 is an orally bioavailable, low-trapping, potent N-methyl-D-aspartate (NMDA) receptor antagonist. The active metabolite of BHV-5000 is lanicemine.
Investigational
AP-001
Investigational
Displaying drugs 1576 - 1600 of 2668 in total